Predictors of recurrence of ventricular tachycardia and the effectiveness of endocardial ablation at the patients with sudden cardiac death and history of myocardial infarction
Main Article Content
Abstract
The aim – to assess predictors of recurrence of ventricular tachycardia after the procedure of endocardial ablation in patients with an episode of cardiac arrest and history of myocardial infarction.
Materials and methods. The work included 32 patients (average age 52.9 ± 5.6 years, 27 (84.3 %) men and 5 (15.6 %) women). Including criteria were: an episode of cardiac arrest with successful resuscitation, history of myocardial infarction, procedure of endocardial mapping with ablation the substrate of tachyarrhythmia. The duration of observation was 12 months. Patients were examined according to the guidelines of the diagnosis in patients with ventricular tachycardia. The endpoint was the recurrence of VT at the time of the patient’s last visit. Quantitative indicators are presented as mean ± standard deviation.
Results. At 12 months after the procedure, the following parameters were associated with relapses of ventricular tachycardia with the greatest statistical significance: left ventricular systolic dysfunction (additive relative risk (ARR) – 43.0 %, relative risk (RR) – 2.57 [1.14–5.82], odds ratio (OR) – 6.50 [7.00–30.70], p < 0.05), arterial hypertension (ARR – 41.0 %, RR – 2.75 [1.08–6.90], OR – 5.96 [1.33–26.70], p < 0.05), diabetes mellitus (ARR – 43.0 %, RR – 2.83 [1.10–7.30], OR – 6.50 [1.25–33.60], p < 0.05), duration of arrhythmic history (ARR – 40.0 %, OR – 5.71 [7.00–28.10], p < 0.05), electrical storm episode at the time of ablation (ARR – 38.0 %, RR – 1.89 [1.27–4.99], OR – 8.57 [7.00–51.50], p < 0.05). Atrial fibrillation (ARR – 25.0 %, RR – 1.58 [0.76–3.25], OR – 2.73 [7.00–17.60], p < 0.05), age younger than 45 years (ARR – 15.0 %, RR – 1.37 [0.60–3.07], OR – 1.78 [7.00–7.47], p < 0.05), and chronic obstructive pulmonary disease (ARR – 18.0 %, RR – 1.46 [0.71–2.99], OR – 2.10 [7.00–9.01], p < 0.05) were at the limit of probability with reliable odds ratio. Recurrent VT was recorded more often in patients with partial intraoperative effect than in those with complete effect (26.7 % versus 5.9 % of patients, p < 0.05). Recurrences of VT were also more common in patients with larger number of radiofrequency ablation procedures in the history (46.7 % versus 5.9 %). A significant risk factor for a recurrent episode of tachycardia was also the duration of corrected QT-interval (QTc, ms) and the presence of late potentials from the epicardial surface of the left ventricle. In the multivariate model, all the above-mentioned parameters were tested, while the only factor independently associated with VT recurrence was the fact of an electrical storm at the time of ablation (risk ratio 5.78; 95 % CI: 1.16–19.4; p = 0.02).
Conclusions. Factors associated with an increased risk of recurrence of ventricular tachyarrhythmias in patients after a heart attack and an episode of sudden death include left ventricular systolic dysfunction, arterial hypertension, diabetes mellitus, and duration of an arrhythmic history. The presence of an electrical storm is an independent predictor of VT relapse when observed up to 12 months after endocardial ablation.
Article Details
Keywords:
References
Berruezo A, Falasconi G, Penela D. A further step toward the spread of ventricular tachycardia substrate ablation during stable rhythm. JACC Clin Electrophysiol. 2023;9(6):848-50. https://doi.org/10.1016/j.jacep.2022.12.013. DOI: https://doi.org/10.1016/j.jacep.2022.12.013
Bhaskaran A, Campbell T, Virk S, Bennett RG, Kizana E, Kumar S. Electrophysiologic and electroanatomic characterization of ventricular arrhythmias in non-compaction cardiomyopathy: a systematic review. J Cardiovasc Electrophysiol. 2021;32(5):1421-9. https://doi.org/10.1111/jce.15026. DOI: https://doi.org/10.1111/jce.15026
Bourier F. Catheter ablation of ventricular tachycardia-Update 2023. Herz. 2023;48(3):247-56. https://doi.org/10.1007/s00059-023-05167-5. DOI: https://doi.org/10.1007/s00059-023-05167-5
Chugh SS, Reinier K, Uy-Evanado A, Chugh HS, Elashoff D, Young C, Salvucci A, Jui J. Prediction of sudden cardiac death manifesting with documented ventricular fibrillation or pulseless ventricular tachycardia. JACC Clin Electrophysiol. 2022;8(4):411-23. https://doi.org/10.1016/j.jacep.2022.02.004. DOI: https://doi.org/10.1016/j.jacep.2022.02.004
Ezzeddine FM, Darlington AM, DeSimone CV, Asirvatham SJ. Catheter ablation of ventricular fibrillation. Card Electrophysiol Clin. 2022 Dec;14(4):729-42. https://doi.org/10.1016/j.ccep.2022.06.002. DOI: https://doi.org/10.1016/j.ccep.2022.06.002
Gordon JS, Maynes EJ, Choi JH, Wood CT, Weber MP, Morris RJ, Massey HT, Tchantchaleishvili V. Ventricular arrhythmias following continuous-flow left ventricular assist device implantation: a systematic review. Artif Organs. 2020;44(8):E313-E325. https://doi.org/10.1111/aor.13665. DOI: https://doi.org/10.1111/aor.13665
Grytsay ON, Todurov BM, Skybchyk YV, Shorikova DV, Shorikov EI. The role of left ventricular hypertrophy, rs1801253 and rs1801252 allelic polymorphisms of adrb1 in assessing the risk of sudden cardiac death in patients with arterial hypertension. Wiad Lek. 2023;76(9):2054-60. https://doi.org/10.36740/WLek202309122. DOI: https://doi.org/10.36740/WLek202309122
Guandalini GS, Liang JJ, Marchlinski FE. Ventricular tachycardia ablation: past, present, and future perspectives. JACC Clin Electrophysiol. 2019;5(12):1363-83. https://doi.org/10.1016/j.jacep.2019.09.015. DOI: https://doi.org/10.1016/j.jacep.2019.09.015
Ho CY, McMurray JJV, Cirino AL, Colan SD, Day SM, Desai AS, Lipshultz SE, MacRae CA, Shi L, Solomon SD, Orav EJ, Braunwald E; VANISH trial investigators and executive committee. The design of the valsartan for attenuating disease evolution in early sarcomeric hypertrophic cardiomyopathy (VANISH) trial. Am Heart J. 2017;187:145-55. https://doi.org/10.1016/j.ahj.2017.02.008. DOI: https://doi.org/10.1016/j.ahj.2017.02.008
Kuck KH, Schaumann A, Eckardt L, Willems S, Ventura R, Delacrétaz E, Pitschner HF, Kautzner J, Schumacher B, Hansen PS; VTACH study group.Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. Lancet. 2010;375(9708):31-40. https://doi.org/10.1016/S0140-6736(09)61755-4. DOI: https://doi.org/10.1016/S0140-6736(09)61755-4
Kumar S, Baldinger SH, Romero J, Fujii A, Mahida SN, Tedrow UB, Stevenson WG. Substrate-based ablation versus ablation guided by activation and entrainment mapping for ventricular tachycardia: a systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2016;27(12):1437-47. https://doi.org/10.1111/jce.13088. DOI: https://doi.org/10.1111/jce.13088
Li L, Ding L, Wu L, Zheng L, Zhou L, Zhang Z, Xiong Y, Zhang Z, Yao Y. Efficacy of catheter ablation for ventricular tachycardia in ischemic cardiomyopathy patients without an ICD implantation. Heart Rhythm. 2024:S1547-5271(24)02553-0. https://doi.org/10.1016/j.hrthm.2024.05.011. DOI: https://doi.org/10.1016/j.hrthm.2024.05.011
Lozano-Granero C, Hirokami J, Franco E, Tohoku S, Matía-Francés R, Schmidt B, Hernández-Madrid A, Zamorano Gómez JL, Moreno J, Chun J. Case series of ventricular tachycardia ablation with pulsed-field ablation: pushing technology further (into the ventricle). JACC Clin Electrophysiol. 2023;9(9):1990-4. https://doi.org/10.1016/j.jacep.2023.03.024. DOI: https://doi.org/10.1016/j.jacep.2023.03.024
Morita H, Asada S, Ueoka A, Mizuno T, Masuda T, Miyamoto M, Kawada S, Nakagawa K, Nishii N, Yuasa S. Risk stratification for the occurrence of ventricular fibrillation in patients with early repolarization syndrome. Heart Rhythm. 2024;S1547-5271(24)02535-9. https://doi.org/10.1016/j.hrthm.2024.04.101. DOI: https://doi.org/10.1016/j.hrthm.2024.07.116
Müssigbrodt A, Grothoff M, Dinov B, Kosiuk J, Richter S, Sommer P, Breithardt OA, Rolf S, Bollmann A, Arya A, Hindricks G. Irrigated tip catheters for radiofrequency ablation in ventricular tachycardia. Biomed Res Int. 2015;2015:389294. https://doi.org/10.1155/2015/389294. DOI: https://doi.org/10.1155/2015/389294
Noordman ABP, Rienstra M, Blaauw Y, Mulder BA, Maass AH. Sex differences in outcomes of patients with an implantable cardioverter-defibrillator for the secondary prevention of sudden cardiac death. J Cardiovasc Dev Dis. 2024;11(4):116. https://doi.org/10.3390/jcdd11040116. DOI: https://doi.org/10.3390/jcdd11040116
Presciutti A, Siry-Bove B, Newman MM, Elmer J, Grigsby J, Masters KS, Shaffer JA, Vranceanu AM, Perman SM. Qualitative study of long-term cardiac arrest survivors’ challenges and recommendations for improving survivorship. J Am Heart Assoc. 2022;11(14):e025713. Published online 2022 Jul 8. https://doi.org/10.1161/JAHA.121.025713. DOI: https://doi.org/10.1161/JAHA.121.025713
Reinier K, Moon JY, Chugh HS, Sargsyan A, Nakamura K, Norby FL, Uy-Evanado A, Talavera GA, Gallo LC, Daviglus ML, Hadduck K, Shepherd D, Salvucci A, Kaplan RC, Chugh SS. Risk factors for sudden cardiac arrest among hispanic or latino adults in southern california: ventura PRESTO and HCHS/SOL. J Am Heart Assoc. 2023;12(20):e030062. Published online 2023 Oct 17. https://doi.org/10.1161/JAHA.123.030062. DOI: https://doi.org/10.1161/JAHA.123.030062
Santangeli P, Shirai Y. Catheter ablation of ventricular tachycardia in patients with ventricular assist devices: a therapy ready for prime time. JACC Clin Electrophysiol. 2019;5(1):52-4. https://doi.org/10.1016/j.jacep.2018.09.011. DOI: https://doi.org/10.1016/j.jacep.2018.09.011
Stanciulescu LA, Vatasescu R. Ventricular tachycardia catheter ablation: retrospective analysis and prospective outlooks – a comprehensive review. Biomedicines. 2024;12(2):266. https://doi.org/10.3390/biomedicines12020266. DOI: https://doi.org/10.3390/biomedicines12020266
Stiles MK, Wilde AAM, Abrams DJ, Ackerman MJ, Albert CM, Behr ER, Chugh SS, Cornel MC, Gardner K, Ingles J, James CA, Jimmy Juang JM, Kääb S, Kaufman ES, Krahn AD, Lubitz SA, MacLeod H, Morillo CA, Nademanee K, Probst V, Saarel EV, Sacilotto L, Semsarian C, Sheppard MN, Shimizu W, Skinner JR, Tfelt-Hansen J, Wang DW. 2020 APHRS/HRS expert consensus statement on the investigation of decedents with sudden unexplained death and patients with sudden cardiac arrest, and of their families. J Arrhythm. 2021;37(3):481-534. https://doi.org/10.1002/joa3.12449. DOI: https://doi.org/10.1002/joa3.12449
Te-Rosano ALD, Chung FP, Lin YJ, Chen SA. Outcomes of catheter ablation of left ventricular summit arrhythmias. Card Electrophysiol Clin. 2023;15(1):85-92. https://doi.org/10.1016/j.ccep.2022.07.003. DOI: https://doi.org/10.1016/j.ccep.2022.07.003
Tung R, Josephson ME, Reddy V, Reynolds MR; SMASH-VT Investigators. Influence of clinical and procedural predictors on ventricular tachycardia ablation outcomes: an analysis from the substrate mapping and ablation in Sinus Rhythm to Halt Ventricular Tachycardia Trial (SMASH-VT). J Cardiovasc Electrophysiol. 2010;21(7):799-803. https://doi.org/10.1111/j.1540-8167.2009.01705.x. DOI: https://doi.org/10.1111/j.1540-8167.2009.01705.x
Vytrykhovskyi AI, Fedorchenko MV. Ventricular ectopic activity – a predictor of sudden cardiac death in patients with atrial fibrillation and post-infarction left ventricular aneurisms. Wiad Lek. 2022;75(9 pt 1):2163-9. https://doi.org/10.36740/WLek202209121. DOI: https://doi.org/10.36740/WLek202209121
Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, Charron P, Corrado D, Dagres N, de Chillou C, Eckardt L, Friede T, Haugaa KH, Hocini M, Lambiase PD, Marijon E, Merino JL, Peichl P, Priori SG, Reichlin T, Schulz-Menger J, Sticherling C, Tzeis S, Verstrael A, Volterrani M; ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43:3997-4126. https://doi.org/10.1093/eurheartj/ehac262. DOI: https://doi.org/10.1093/eurheartj/ehac262